+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07856706

Study of ABBV-7828 Safety, Tolerability, and Food Effects in Healthy Adults with Single Doses

Led by AbbVie · Updated on 2026-10-29

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying ABBV-7828 to assess its safety, how well it is tolerated, how it behaves in the body, and how food intake affects it in healthy adults. This Phase 1 study involves healthy participants aged 18 to 65 years with a body mass index between 18.0 and 32.0 kgm2. The study is randomized and double-blinded, and it compares ABBV-7828 to a placebo. Participants will receive single oral doses of ABBV-7828 or placebo. The study includes two periods where participants receive ABBV-7828 either while fasting or after a high-fat, high-calorie meal to evaluate the effect of food on the drugs pharmacokinetics. The dosing is done sequentially with some participants receiving ABBV-7828 first in fasting conditions followed by fed conditions, and others in the reverse order. Participants will be monitored for adverse events for up to about 38 days and have blood tests to measure drug levels and how the body processes ABBV-7828 over approximately 10 days. Assessments include safety evaluations such as vital signs, ECG, and laboratory tests. The overall study participation duration depends on these follow-up periods, with close monitoring to understand the drugs behavior and safety profile.

CONDITIONS

Brief Title

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here